ACT Genomics is an innovation –driven cancer solution provider in Asia with offices in Taipei, Singapore, Hong Kong & Tokyo. With our Next-Generation Sequencing (NGS) technology and experienced bioinformatics team, we provide optimal cancer treatment planning, cancer relapse and drug resistance monitoring, cancer risk assessment and immunotherapy evaluation to medical professionals. Our team is specialized in biomarker identification, underlying disease mechanism discovery and genetic alteration exploration for academia around the world. Pharmaceutical communities also benefit from our expertise in identifying targets for drug development, stratifying patients for clinical studies and delineating drug responses with efficiency and efficacy. We ‘turn genomics into action’.